An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection

Trial Profile

An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2015

At a glance

  • Drugs Cipargamin (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 16 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 18 Jul 2014 As per Consensus agreement of a Data Monitoring Committee (DMC), 3 three more cohorts are added to obtain more safety data of next three dosage levels.
    • 18 Jul 2014 Planned number of patients changed from 10 to 48 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top